Feature | February 18, 2013

Promus Premier DES Receives European Approval

The next advance in durable polymer stent technology offers easier delivery, flexibility

February 18, 2013 — Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES) technology. The Promus Premier is designed to improve DES performance with a new delivery system and redesigned stent architecture that improves radial, axial strength and deliverability.

The new stent uses the same drug and polymer as the Promus Element, which Boston Scientific said compares very well in trials to the market leading competitor, Abbott’s Xience V. The company said the Promus Premier is being marketed as a workhorse stent.

Coronary heart disease is a narrowing of the vessels that supply blood and oxygen to the heart. Recent statistics from the European Heart Network and the European Society of Cardiology show it is the single most common cause of death in Europe accounting for 1.8 million deaths in Europe per year. Patients living with coronary heart disease, also known as coronary artery disease, may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.  

"The customized platinum chromium stent architecture maintains the superior visibility, exceptional radial strength and fracture resistance, minimal recoil and outstanding clinical outcomes of a PtCr everolimus-eluting stent while offering improved longitudinal strength," said John Ormiston, M.D., Mercy Angiography, Auckland City, New Zealand. "In addition, the enhanced stent delivery system offers improved deliverability. Stent design is a balance of trade-offs and the Promus Premier Stent System appears to have it right."

The Promus Premier Stent System was developed with input from physicians. The customized platinum chromium alloy stent architecture provides strength without compromising flexibility. An enhanced low-profile delivery system features a shorter, more visible tip, dual-layer balloon and bi-segment inner lumen catheter designed to facilitate precise stent delivery across challenging lesions. The Everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials demonstrating long-term safety and efficacy. The Platinum Workhorse Trial compared the Promus Element stent (platinum chromium everolimus-eluting stent) to the Xience V stent (cobalt chromium everolimus-eluting stent), and demonstrated that platinum chromium technology has superior clinical outcomes between years one and two.

The Promus Premier Stent System is currently offered in a matrix of 47 sizes, ranging in diameter from 2.25 to 4 mm and lengths of 8 to 38 mm on a monorail catheter platform. This comprehensive offering provides cardiologists and their patients a broad range of options designed to best suit their needs. The Promus Premier Stent System is not available for sale in the United States or Japan.

For more information: www.bostonscientific.com

Related Content

smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Teleflex, AVA 2016 Congress, Association for Vascular Access
News | Vascular Access| September 20, 2016
September 20, 2016 — Teleflex Inc.
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Shockwave medical, lithoplasty
News | Cath Lab| September 19, 2016
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a singl
Overlay Init